Comparison of Response and Dosimetry between different Radiotherapy schedules in High Grade Glioma

Comparison of Response and Dosimetry between Sequential Boost and Simultaneous Integrated Boost (with two different dose schedules) in Radiotherapy for High Grade Gliomas - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094953

Enrollment

Registered

2025-09-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C71- Malignant neoplasm of brain

Interventions

Intervention1: Sequential Boost: Sequential Boost Radiotherapy with PTV1 46Gy/23#/5weeks followed by PTV2 Boost with 14Gy/7#/2weeks with Concurrent Temozolomide orally 75mg per m2 Control Intervention

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients of biopsy proven non metastatic high grade glioma 2. ECOG Performance Status 0 to 2. 3. Normal baseline hematological and biochemical parameters 4. Patients willing to provide informed consent with signature or left thumb impression for the approval for inclusion in the study.

Exclusion criteria

Exclusion criteria: 1. Evidence of distant metastasis by clinical or radiographic means. 2. Prior Radiotherapy 3. History of prior malignancy. 4. Pre-existing uncontrolled co-morbid medical conditions like Diabetes mellitus, cardiac ailments, neurological ailments for which deviation from oncological treatment protocol is required. 5. Patient refusal to undergo radiation. 6. Pregnancy or Lactation. 7. Other synchronous or metachronous primary malignancy. 8. Allergy to iodinated IV contrast or gadolinium.

Design outcomes

Primary

Measure	Time frame
To compare response assessment, toxicity profiles, OS, PFS, dosimetric analysis and neurocognitive function in patients receiving Sequential Boost and Simultaneous Integrated Boost Radiotherapy (with two different dose schedules) in High Grade GliomasTimepoint: 24months	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Shatarupa Chattopadhyay

R G Kar Medical College and Hospital, Kolkata

drshatarupadutta@gmail.com8910383179

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026